DERM

Journey Medical Corp. Common Stock (DERM) | Rumor.io

Journey Medical

DERM

Attention (50-day avg)0%

Attention rank (50-day avg)#2,302

Bullish sentiment (50-day avg)95%

Price to earnings ratio39.1

Market capitalization181.5M

Earnings per share-0.22

Dividend yield (TTM)—

Revenue (annual)61.9M

Net income (annual)-11.4M

Social

What share of all stock conversation is about DERM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 12

Earnings beat with revenue and EPS growth, driven by increasing insurance coverage and prescription volume.
The company's new product, Emrosi, has reached a monthly high of 14,000 prescriptions in July, with a large national health plan adding it to their formulary in early August.
Q3 and Q4 sales are expected to explode, with Qbrexza also expected to see an uptick in sales, and Accutane holding up despite generic erosion.

Generated by AI

Sentiment

Of the messages about DERM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	77.78% -22.22	89.47% -6.18	88.32% +1.97
Bearish	0%	22.22% +22.22	10.53% +6.18	11.68% -1.97

Nov 4

The company's decision to avoid dilution through non-dilutive capital is a positive move for shareholders.
The approval of the company's product is expected to lead to a steady climb in the stock price, with potential for institutional investors to get in and drive the price up.
The company's focus on developing its Emrosi product, which is expected to offset declining revenue from other products, is seen as a smart move that will ultimately benefit shareholders.

Generated by AI

Topics

Of the messages about DERM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	54.32%
Earnings	—	—	—	20.37%
Analysts	—	—	—	6.79%
Controversies	—	—	—	1.85%
Macro	—	—	—	5.56%
Technical Analysis	—	—	—	11.11%

Jan 13

Journey Medical Corporation has acquired VYNE Therapeutics' Molecule Stabilizing Technology franchise, including two FDA-approved topical minocycline products, for an upfront payment of $20 million and potential milestone payments of up to $450 million.
The acquisition expands Journey Medical's portfolio to nine marketed dermatology products and is expected to be accretive to the company's model.
The deal is seen as a strategic move for Journey Medical, with the company's sales force and expertise in the dermatology space expected to boost sales of the acquired products.

Generated by AI

Community

Of the messages about DERM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	83.33%	70%	57.65%
Newcomers	0%	16.67%	30%	42.35%

Regulars· Jun 13

$DERM is down 10.27% at $2.0099, with a significant drop in volume, and recent news about a positive topline data from a Phase 1 clinical trial assessing the impact of DFD-29.
Journey Medical Corporation's stock, $DERM, has gained over 26% since earlier in the day, and the price may continue to rise.
The stock has seen an abrupt price boost on above-average volume, with the price currently at $1.92, up 15% since the previous day's close, and a recent news announcement has contributed to this increase.

Newcomers· Jun 13

New investors are excited about Journey Medical Corporation's ($DERM) trading performance, with one user noting a gain from an airplane trade.
Another newcomer is sharing trade ideas, combining $DERM with $AGRX, citing good news and a potential big day ahead.
Users are discussing Journey Medical Corporation's ($DERM) positive Phase 1 clinical trial data and the potential for a successful Phase III trial, with some expressing optimism about the stock's future performance.

Generated by AI

News

Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM)

Journey Medical (DERM) is rated Buy, driven by Emrosi’s rapid prescription growth and expanding payer coverage.

10d agoSeeking Alpha

Journey Medical at H.C. Wainwright: emrosi drives growth

15d agoInvesting.com

Journey Medical Corporation to Participate in September 2026 Investor Conferences

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of

21d agoca.finance.yahoo.com

Journey Medical (DERM) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Journey Medical Emrosi growth drives a 23% Q2 revenue jump and positive EBITDA. Click for more on DERM stock.

1mo agoSeeking Alpha

Why is Journey Medical stock rallying today?

1mo agoInvesting.com

Also Discussed

Investors talking about DERM also mention

#	Name	Attention
1	Fortress Biotech, Inc.FBIO	0%0
2	CKPT - Checkpoint Therapeutics, Inc.	——
3	Avenue Therapeutics Inc.ATXI	0%new
4	Fortress Biotech Inc. Preferred Stock 9.375% PerpetualFBIOP	0%0
5	Mustang Bio Inc.MBIO	0%0
6	Arcutis Biotherapeutics, Inc.ARQT	0%+0
7	OPTN - OptiNose, Inc.	——
8	SWTX - SpringWorks Therapeutics, Inc.	——
9	Ars Pharmaceuticals IncSPRY	0%0
10	Atara Biotherapeutics, Inc.ATRA	0%0

Journey Medical Corp. Common Stock

Healthcare
Drug Manufacturers - Specialty & Generic

Journey Medical Corp. Common Stock represents the equity of Journey Medical Corporation, a commercial-stage pharmaceutical company focused on developing, marketing, and selling prescription products for dermatological conditions in the United States. The company’s portfolio includes branded and authorized generic treatments used in areas such as acne, hyperhidrosis, fungal infections, and other skin disorders. Its current product lineup includes therapies such as Qbrexza, Accutane, Amzeeq, Targadox, Ximino, Zilxi, Exelderm, and Luxamend, reflecting a business centered on specialty dermatology care. Journey Medical Corp. serves a focused market within the broader pharmaceutical sector by commercializing FDA-approved products designed for physician-prescribed use. The stock is associated with a small-cap healthcare company whose role in the market is tied to the distribution and commercialization of dermatology medicines rather than broad consumer health products.

Website

Location

9237 East Via de Ventura Blvd.

Scottsdale, AZ, 85258

United States

Social

What share of all stock conversation is about DERM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 12

Earnings beat with revenue and EPS growth, driven by increasing insurance coverage and prescription volume.
The company's new product, Emrosi, has reached a monthly high of 14,000 prescriptions in July, with a large national health plan adding it to their formulary in early August.
Q3 and Q4 sales are expected to explode, with Qbrexza also expected to see an uptick in sales, and Accutane holding up despite generic erosion.

Generated by AI

Sentiment

Of the messages about DERM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	77.78% -22.22	89.47% -6.18	88.32% +1.97
Bearish	0%	22.22% +22.22	10.53% +6.18	11.68% -1.97

Nov 4

The company's decision to avoid dilution through non-dilutive capital is a positive move for shareholders.
The approval of the company's product is expected to lead to a steady climb in the stock price, with potential for institutional investors to get in and drive the price up.
The company's focus on developing its Emrosi product, which is expected to offset declining revenue from other products, is seen as a smart move that will ultimately benefit shareholders.

Generated by AI

Topics

Of the messages about DERM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	54.32%
Earnings	—	—	—	20.37%
Analysts	—	—	—	6.79%
Controversies	—	—	—	1.85%
Macro	—	—	—	5.56%
Technical Analysis	—	—	—	11.11%

Jan 13

Journey Medical Corporation has acquired VYNE Therapeutics' Molecule Stabilizing Technology franchise, including two FDA-approved topical minocycline products, for an upfront payment of $20 million and potential milestone payments of up to $450 million.
The acquisition expands Journey Medical's portfolio to nine marketed dermatology products and is expected to be accretive to the company's model.
The deal is seen as a strategic move for Journey Medical, with the company's sales force and expertise in the dermatology space expected to boost sales of the acquired products.

Generated by AI

Community

Of the messages about DERM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	83.33%	70%	57.65%
Newcomers	0%	16.67%	30%	42.35%

Regulars· Jun 13

$DERM is down 10.27% at $2.0099, with a significant drop in volume, and recent news about a positive topline data from a Phase 1 clinical trial assessing the impact of DFD-29.
Journey Medical Corporation's stock, $DERM, has gained over 26% since earlier in the day, and the price may continue to rise.
The stock has seen an abrupt price boost on above-average volume, with the price currently at $1.92, up 15% since the previous day's close, and a recent news announcement has contributed to this increase.

Newcomers· Jun 13

New investors are excited about Journey Medical Corporation's ($DERM) trading performance, with one user noting a gain from an airplane trade.
Another newcomer is sharing trade ideas, combining $DERM with $AGRX, citing good news and a potential big day ahead.
Users are discussing Journey Medical Corporation's ($DERM) positive Phase 1 clinical trial data and the potential for a successful Phase III trial, with some expressing optimism about the stock's future performance.

Generated by AI

Journey Medical

Social

Aug 12

Nov 4

Jan 13

Regulars· Jun 13

Newcomers· Jun 13

Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM)

Journey Medical at H.C. Wainwright: emrosi drives growth

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical (DERM) Q2 2026 Earnings Call Transcript

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Why is Journey Medical stock rallying today?

Also Discussed

Journey Medical Corp. Common Stock

Company Information

Location

Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM)

Journey Medical at H.C. Wainwright: emrosi drives growth

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical (DERM) Q2 2026 Earnings Call Transcript

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Why is Journey Medical stock rallying today?

Also Discussed

Social

Aug 12

Nov 4

Jan 13

Regulars· Jun 13

Newcomers· Jun 13